Facilitation of drug evaluation in children by population methods and modelling.
about
A Delphi process to optimize quality and performance of drug evaluation in neonatesProposals for model-based paediatric medicinal development within the current European Union regulatory frameworkPharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.The pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion.Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling.Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children.Challenges in conducting clinical trials in children: approaches for improving performanceTips and traps analyzing pediatric PK data.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyInterspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.Physiologically based pharmacokinetic modeling and simulation in pediatric drug developmentPaediatric pharmacokinetics: key considerations.Predicting pediatric age-matched weight and body mass indexOseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unitShort versus long infusion of meropenem in very-low-birth-weight neonatesEffect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenPharmacokinetic studies in infants using minimal-risk study designsHow to optimize the evaluation and use of antibiotics in neonatesSingle-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults.External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.Population pharmacokinetics of abacavir in infants, toddlers and children.A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young InfantsPharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.Dosing in children.The role of population PK-PD modelling in paediatric clinical research.Advances in paediatric pharmacokinetics.Dried blood spots, pharmacokinetic studies and better medicines for children.My child is unique; the pharmacokinetics are universal.Physiologically based pharmacokinetic (PBPK) modeling in children.Fundamentals of population pharmacokinetic modelling: modelling and software.Prediction of morphine clearance in the paediatric population : how accurate are the available pharmacokinetic models?Population pharmacokinetic analysis during the first 2 years of life: an overview.Methods for pharmacokinetic analysis in young children.Tailored tools to improve pharmacotherapy in infants.Dosage individualization in children: integration of pharmacometrics in clinical practice.Prediction of drug clearance in children.Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.Considerations when using pharmacokinetic/pharmacodynamic modeling to determine the effectiveness of simple analgesics in children.Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.
P2860
Q28542934-81DED7B0-435C-42B8-8568-2A894BCBC18EQ28749999-73FC6C8D-E62D-4658-A9C2-57C27144D56EQ30249512-0FB95B19-A114-41C8-8499-2EDAFE67BC49Q30456107-8E1E9A45-F969-4CE3-8624-9E0EFFD94F10Q30938796-733FBBBD-357A-4191-892A-362E0D9FDCE3Q33574626-CFEB78D3-8CF4-4BE9-A86E-ECC8FE083247Q33717140-DB44F372-85EB-42D5-AC82-8E2D78BA411CQ33820152-B958348D-A7C1-42AF-9060-8C94ED3E31C7Q33827819-B6901610-27B6-489E-8FC0-2281F9D22AC1Q34299078-BFCCF930-3415-4AB0-B1E5-C7082225CBE0Q34658074-7BEA1075-D73F-41E6-A598-C678F7BBE977Q35135940-CC473A43-9249-4ED7-A0FA-CA59132F4AA9Q35318223-48CFD3C4-40E1-40B6-9D43-A46EF226836CQ36086446-16A73BCF-5B82-49DE-A550-8307BEC0278EQ36172523-9F57DB15-317F-465F-99D7-DC86AB87BA48Q36322918-E6425A40-06CB-4ABC-B691-65E102DE67B1Q36438116-D7C446A5-4696-4199-AFB9-4A99042D46F1Q36452369-BCFA2F3F-9356-43AF-952A-41FF543D009CQ36688528-FE76191A-4D2A-46B5-B10B-3F34E21393FCQ36729959-F59156E8-4D52-4AA3-9513-FC905A808FD0Q36948138-41C762C9-337A-48E5-BC77-BEB5D5984075Q37358644-3958E285-1DC4-4027-BDA0-C06D9F0B6D05Q37544499-104E61C8-C331-4480-93B4-859C0072B704Q37678918-D785C7FE-8513-4EA8-BC9D-0313A3AF5698Q37719346-CB6DEDEC-B3C5-4820-A766-48F4666D3299Q37813680-1B5ACBE3-6D0D-4B89-825A-1420A1F4C0B9Q37859735-540A9783-BF75-46F0-9207-762CEF8D68D5Q37973872-85D3F1A4-D322-4BF1-B41E-34FEC416B0CCQ38016332-4EE32803-94B8-422E-B62C-AF785D749774Q38016955-50EF0FBB-DB5B-437E-B2D9-B5D0CA69846EQ38047202-91C545CA-C24D-412B-9A51-A34530E96DA5Q38062388-00BE3F94-16CF-48FB-9567-2B8F3EF9865DQ38187157-CF37A0F7-17A6-4617-B819-3BADDAF0BC33Q38222870-8463B5B4-BAFC-49C7-8663-70577340CEB4Q38240055-44DFBC7B-4D48-42E6-96D4-36E309588339Q38365645-4FD54100-A074-4B26-824D-D7DCE77DC753Q38371961-9864CBA0-1DF1-42BA-9F10-C4BCE72BFC95Q38527434-1C8C8B57-3D92-4142-A8C9-9199BCF4115AQ38544082-35570002-3251-4449-8865-D4F60537AF99Q38696468-521B18F8-356D-4A82-A08B-DC255DFBB7A8
P2860
Facilitation of drug evaluation in children by population methods and modelling.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Facilitation of drug evaluation in children by population methods and modelling.
@en
Facilitation of drug evaluation in children by population methods and modelling.
@nl
type
label
Facilitation of drug evaluation in children by population methods and modelling.
@en
Facilitation of drug evaluation in children by population methods and modelling.
@nl
prefLabel
Facilitation of drug evaluation in children by population methods and modelling.
@en
Facilitation of drug evaluation in children by population methods and modelling.
@nl
P2093
P1476
Facilitation of drug evaluation in children by population methods and modelling.
@en
P2093
Gérard Pons
Michel Tod
Vincent Jullien
P2860
P304
P356
10.2165/00003088-200847040-00002
P577
2008-01-01T00:00:00Z
P6179
1052859289